Heparinoids

• REFERENCES

• 1 Hauschild F. Pharmakologie und Grundlagen der Toxikologie. Leipzig: VEB G Thiemc; 1960: 488.
• 2 Walenga JM, Hoppensteadt D, Fareed J. Non heparin glycosaminoglycan derived drugs: A biochemical and pharmacological perspective. Semin Throm Hemost 1991; 17 (Suppl. 02) 137-42.
• 3 Bianchini P, Osima P. Study of one heparinoid of the duodenal mucosa. Bull Societa Italiana di Biologia sperimentale, 1958; 34: 1-15.
• 4 Marcum JA, Rosenberg RD. The biochemistry, cell biology and pathophysiology of anti-coagulantly active heparinlike molecules of the vessel wall. In: Heparin. Lane DA, Lindahl U. (eds) Boca Raton, FL: CRC Press; 1989: 275-94.
• 5 Hoppensteadt D, Racanelli A, Walenga JM, Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Semin Thromb Hemost 1989; 15: 378-85.
• 6 Sirtori CR. Pharmacology of sulfomucopoly-saccharides in atherosclerosis prevention and treatment. In: Selectivity and risk/benefit assessment of hyperlipidemia drugs. Ricci G. et al. (eds) New York: Raven Press; 1982: 189-94.
• 7 Fareed J, Hoppensteadt D, Walenga JM. et al. Molecular and functional heterogeneity in dermatan sulfate preparations. Semin Thromb Hemost 1991; 17 (Suppl. 02) 174-80.
• 8 Malsch R, Harenberg J. Considerations about the correct nomenclature of glycos-aminoglycans. Thromb Haemost 1993; 18: 718-9.
• 9 Dol F, Petitou M, Lormeau JC. Pharmacological properties of a low molecular weight dermatan sulfate (4 kDa): Comparison with unfractionated dermatan sulfate (25 kDa). J Clin Med 1990; 115: 43-51.
• 10 Tollefsen DM, Pestka CA, Monafo WJ, Monafo J. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6.
• 11 Ofosu FA, Fernandez F, Gauthia D, Buchanan M. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic anticoagulant effects of heparin and dermatan sulfate. Semin Thromb Haemost 1985; 11: 1333-7.
• 12 Fernandez J, Van Ryn R, Ofosu FA. et al. The haemorrhagic and antithrombotic effects of dermatan sulfate. Br J Haematol 1986; 64: 309-17.
• 13 Hoppensteadt D, Walenga JM, Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Thromb Res 1990; 60: 191-200.
• 14 Buchanan MR, Liao P, Smith LJ, Ofosu FA. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II dependent thrombin inhibitors: Importance of heparin cofactor II. Thromb Res 1994; 74: 463-75.
• 15 Carrie D, Caranobe C, Gabeig AM. et al. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit. Thromb Haemost 1992; 68: 637-41.
• 16 Brister SJ, Ofosu FA, Heigenhauser GJF. et al. Is heparin the ideal anticoagulant for cardiopulmonary bypass?. Dermatan sulfate may be an alternate choice. Thromb Haemost 1994; 71: 468-73.
• 17 Cosmi B, Agnelli G, Young E. et al. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate. Thromb Haemost 1993; 443-7.
• 18 Bendayan P, Boccalon H, Dupuy D, Boneii B. Dermatan sulfate is a more potent inhibitor of clot bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost 1994; 71: 576-80.
• 19 Gianese F, Lucchelli P. A survey of the clinical experience with dermatan sulfate. Semin Thromb Hemost 1991; 17 (Suppl. 02) 199-204.
• 20 Bergonzini GL, Bianchini P, Hoppensteadt D. et al. Pharmacokinetics of native and low molecular weight dermatans: preliminary studies in rats and primates. Semin Thromb Haemost 1991; 17 (Suppl. 02) 235-9.
• 21 Dettoli AG, Galli G, Manotti C, Palazzini E. Pharmacological activity of a low molecular weight dermatan sulfate (Desmin) in healthy volunteers. Semin Thromb Hemost 1994; 20: 259-65.
• 22 Barbanti A, Calanni F, Milani MR. et al. Therapeutic effect of a low molecular weight dermatan sulfate (Desmin 370) in rat venous thrombosis. Evidence for an anticoagulant independent mechanism. Thromb Haemost 1993; 69: 147-51.
• 23 Meuleman DG, Hobbelem PMJ, van Dedem G, Moelker HCT. A novel antithrombotic heparinoid (Org 10172) devoid of bleeding enhancing capacity. A survey of its pharmacologic properties in experimental animal models. Thromb Res 1982; 27: 353-63.
• 24 Fernandez FA, Buchanan MR, Hirsh J. et al. Catalysis of thrombin inhibition provides an index for estimating the anti thrombotic potential of glycosaminoglycans in rabbits. Thromb Haemost 1987; 57: 286-93.
• 25 Van Dinther TG, Hol F, Meuleman DG. Effect of various heparin(oids) on heparin cofactor II mediated anti-thrombin activity and inhibition of thrombin generation in vitro. Thromb Haemost 1987; 58: 423.
• 26 Harenberg J, Würzner B, Zimmermann R, Schettler G. Bioavailability and antagonisa-tion of the low molecular weight heparin CY 216 in man. Thromb Res 1986; 44: 549-54.
• 27 Kroon C, Boer A, Kroon JM. et al. Influence of skin fold thickness on heparin absorption. Lancet 1991; 337: 945-56.
• 28 Danhof M, de Boer A, Magnani HN, Stiekema JCJ. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992; 22: 73-84.
• 29 Stiekema JCJ, Wijnand HP, Ten Cate H. et al. Partial in vivo neutralisation of plasma anticoagulant effects of lomoparan (Org 10172) by protamine chloride. Thromb Res 1991; 63: 157-67.
• 30 Cade JF, Wood M, Magnani HM, Westlake GW. Early clinical experience of a new heparinoid Org 10172 in prevention of deep venous thromboses. Thromb Res 1987; 45: 497-503.
• 31 Hock JA, Nurmohamed MF, Hamelyuck KJ. et al. Prevention of deep venous thromboses following total hip replacement by low molecular heparinoid. Thromb Haemost 1992; 67: 28-32.
• 32 Bergquist D, Kettunen K, Fredin H. et al. Thromboprophylaxis in hip fracture patients – a prospective randomized comparative study between Org 10172 and dextran 70. Surgery 1991; 109: 617-22.
• 33 Gerhart TN, Yett HS, Robertson LK. et al. Low molecular weight heparinoid compared with warfarin for prophylaxis of deep vein thrombosis in patients who are operated on for fracture of the hip. J Bone Joint Surg 1991; 73A: 494-502.
• 34 Gallus A, Murphy W, Nacy J. et al. The influence of Org 10172, an antithrombotic heparinoid on urinary blood loss after transurethral prostatectomy. Thromb Res 1989; 15: 229-38.
• 35 Ten Cate H, Heeney P, Ten Cate JW. et al. Double blind placebo controlled safety study of a low molecular weight heparinoid in patients undergoing transurethral resection of the prostate. Thromb Haemost 1987; 57: 92-6.
• 36 Turpie AGG, Hirsh J, Jay RM. et al. Double blind randomized trial of ORG 10172 low molecular weight heparinoid in prevention of deep vein thrombosis in thrombotic stroke. Lancet 1987; i: 523-6.
• 37 Turpie AGG. Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis 1992; 22: 92-8.
• 38 Estoppey D, Hockreither J, Breyer HG. et al. Org 10172 (Lomoparan) versus heparin-DHE in prevention of thromboembolism in total hip replacement – a multicentre trial. Thromb Haemost 1989; 62: 356.
• 39 Magnani HN. Heparin induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61.
• 40 Chong BH, Ismail F, Cade J. et al. Heparin induced thrombocytopenia: Studies with a low molecular weight heparinoid, Org 10172. Blood 1989; 73: 1592-6.
• 41 Maffrand JP, Herbert JM, Bernart A. et al. Experimental and clinical pharmacology of pentosane polysulfate. Semin Thromb Hemost 1991; 17, Suppl 2: 186-98.
• 42 Fischer AM, Barrowcliffe TW, Thomas DP. A comparison of structures of pentosane polysulphate (SP 54) and heparin, I Mechanism of action on blood coagulation. Thromb Haemost 1982; 47: 104-8.
• 43 Fischer AM, Merton RE, Marsh NA. et al. A comparison of pentosan polysulphate with heparin II. Effects of subcutaneous injection. Thromb Haemost 1982; 47: 109-13.
• 44 Soria C, Soria J, Ryckewaert JJ. et al. Anticoagulant activities of a pentosan polysulfate: Comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 1980; 19: 455-63.
• 45 Ofosu FA, Modi GJ, Hirsh J. et al. Mechanism for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ann NY Acad Sci 1986; 485: 41-56.
• 46 Freyssinet JM, Wiesel ML, Grunebaum L. et al. Activation of human protein C by blood coagulation factor Xa in the presence of anionic phospholipids. Enhancement by sulphated polysaccharides. Biochem J 1989; 261: 341-8.
• 47 Vinazzer H, Stemberger A, Haas S, Blii-mel G. Influence of heparin, of different heparin fractions and of a low molecular weight heparin like substance on the mechanism of fibrinolysis. Thromb Res 1982; 27: 341-52.
• 48 Vinazzer H. Clinical and experimental data on the fibrinolytic action of pentosane poly-sulfate. Haemostasis 1984; 14: 122.
• 49 Klöcking HP, Markwardt F. Pharmacological stimulation of TPA release. Pharmazie 1994; 49: 227-30.
• 50 Klöcking HP. Influence of pentosan polysul-fate sodium compared with other polyan-ionic compounds on the t-PA and PAI 1 activity. Perfusion 1994; 7 Suppl 2: 32-8.
• 51 Hakim A. Activité et tolerance de l’hemo-clar dans la prevention des thromboses veineuses profondes post-operatoires en Phlebologie. Etude sur 3000 cas. Angiologie 1987; 39: 187-9.
• 52 Claude PH, Pescio M. Essai comparatif sur la prevention de la maladie thromboembo-lique post operatone par le polysulfate de pentosane et heparinate de calcium. Gazette Medicale 1984; 91: 136-8.
• 53 Kiesel J, Harbauer GB, Wenzel E. et al. Comparison of the effects of sodium pento-sanpolysulfate and unfractionated heparin on venous thrombosis, an experimental study in rats. Thromb Res 1991; 64: 301-8.
• 54 Szirmai I, Kamondi A, Magyar H, Juhasz C. Untersuchungen von Partienten mit zerebraler Ischämie unter Pentosanpolysulfat (SP 54). Perfusion 1993; 6: 314-20.
• 55 Kollar I, Scholz ME, Rozsos I. Comparison of pentosan polysulfate sodium (Na-PPS) with a low molecular weight heparin in the prevention of venous thrombosis after abdominal surgery. Perfusion 1994; 7: 123-30.
• 56 Vinazzer H. Rezidivprophylaxe zerebro-vaskulärer Thrombosen, eine randomisierte Vergleichsstudie mit Azetylsalizylsäure und Natrium-Pentosanpolysulfat. Fortschr Med 1994; 103: 79-85.
• 57 Herbert JM, Cottineau M, Driot F. et al. Activity of pentosan polysulphate and derived compounds on vascular endothelial cell proliferation and migration induced by acidic and basic FGF in vitro. Biochem Pharmacol 1988; 37: 647-850.
• 58 Klein-Soyer C, Beretz A, Cazenave JH. et al. Sulphated polysaccharides modulate effects of acidic and basic fibroblast growth factors on repair of injured confluent human vascular endothelium. Arteriosclerosis 1989; 9: 147-53.
• 59 Zoller C, Haas S, Blümel G. et al. Antithrombotic glycosaminoglycans augment the in vitro proliferation of human lymphocytes. Perfusion 1994; 7, Suppl 2: 39-44.
• 60 Baici A, Salgam P, Kehr F, Boni A. Inhibition of human elastase from polymorphonuclear leucocytes by gold sodium thiomalate and pentosanpolysulphate (SP 54). Biochem Pharmacol 1981; 30: 703-8.
• 61 Parish CR, Coombe DR, Jakobsen KB. et al. Evidence that sulphated polysaccharides inhibit tumor metastasis by blocking tumour cell derived heparanases. Int J Cancer 1987; 40: 511-8.
• 62 Herbert JM, Maffrand JP. Effect of pentosan polysulphate, standard heparin and related compounds on protein kinase C activity. Biochem Biophys Acta 1991; 1091: 432-41.
• 63 Sydow G, Klöcking HP. Effect of pentosan polysulphate (SP 54) on the reverse transcriptase activity of several retroviruses. Biomed Biochim Acta 1987; 46: 527-30.
• 64 Baba M, Snoeck R, Pauwels R, de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus and human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 1988; 32: 1742-5.
• 65 Clancy J, Tait-Kamradt A, Petitpas J. et al. Assays to detect and characterize human immunodeficiency virus type 1 (HIV-1) receptor antagonists, compounds that inhibit binding of the HIV-1 surface glycoprotein GP 120, to the CD4 receptor on human T lymphocytes. Antimicrobial Agents and Chemotherapy 1994; 38: 2008-13.
• 66 Johann S, Zoller C, Haas S. et al. Sulfated polysaccharide anticoagulants suppress natural killer cell activity in vitro. Thromb Haemost 1995; 74: 998-1002.
• 67 Mulholland SG, Sant GR, Hanno P. et al. Pentosane polysulfate sodium for therapy of interstitial cystitis, a double blind placebo-controlled clinical study. Urology 1990; 35: 552-8.
• 68 Choay J, Lormeau JC, Petitou M. et al. Structural studies on a biologically hexasaccha-ride obtained from heparin. Ann NY Acad Sci 1981; 370: 644-9.
• 69 Riesenfeld J, Thunberg L, Höök M, Lindahl U. The antithrombin binding sequence of heparin. Location of essential N-sulfate groups. J Biol Chem 1981; 256: 2389-94.
• 70 Choay J, Petitou M, Lormeau JC. et al. Structure activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity. Biochem Biophys Res Commun – 1983; 116: 492-9.
• 71 Walenga JM, Bara LC, Petitou M. et al. The inhibition of the generation of thrombin and antithrombotic effect of a pentasaccharide with sole anti factor Xa activity. Thromb Res 1988; 51: 23-33.
• 72 Beguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989; 61: 397-401.
• 73 Petitou M, Lormeau JC, Choay J. A new synthetic pentasaccharide with increased antifactor Xa activity: Possible role for anionic clusters in the interaction of heparin and antithrombin III. Semin Thromb Hemost 1991; 17, Suppl 2: 143-6.
• 74 Carrie D, Caranobe C, Saivin S. et al. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: Comparison with Cy 216. Blood 1994; 84: 2571-7.
• 75 Raake W, Klauser RJ, Elling H, Meinetsber-ger E. Anticoagulant and antithrombotic properties of synthetic sulfated bis-lacto-bionic acid amides. Thromb Res 1989; 56: 719-30.
• 76 Raake W, Klauser RJ, Meinetsberger E. et al. Pharmacologic profile of the antithrombotic and bleeding actions of sulfated lacto-bionic acid amides. Semin Thromb Haemost 1991; 17, Suppl 1: 129-35.
• 77 Raake W, Klauser RJ, Meinberger E. Antithrombotic activities of aprosulate sodium (LW 10082) and its neutralization by protamine. Semin Thromb Haemost 1993; 19, Suppl 1: 83-5.
• 78 Fareed J, Coker S, Iqbal O. et al. Pharmacodynamics of a sulfated lactobionic acid amide-derived antithrombotic agent (Aprosulate) in primates. Semin Thromb Hemost 1991; 17, Suppl 2: 147-52.
• 79 Beguin S, Dol F, Hemker HC. Influence of lactobionic acid on the mimetics of thrombin in human plasma. Semin Thromb Haemost 1991; 17, Suppl 1: 126-8.
• 80 Fareed J. Personal communication.
• 81 Klöcking HP, Hoffmann A, Fareed J. Influence of hypersulfated lactobionic acid amides on tissue plasminogen activator release. Semin Thromb Haemost 1991; 17, 4: 379-84.
• 82 Hoppensteadt D, Walenga JM, Fareed J. Protaminsulfate neutralization of lactobionic acid amides. Semin Thromb Hemost 1991; 17, Suppl 2: 153-7.